Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.33)
# 914
Out of 4,829 analysts
208
Total ratings
48%
Success rate
1.01%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $535 | $424.99 | +25.89% | 3 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $46.45 | +18.41% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $527.78 | +31.68% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $22.28 | +7.72% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $31.16 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $75.97 | +11.89% | 11 | Apr 22, 2025 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $975 | $734.57 | +32.73% | 12 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $96.91 | +28.99% | 15 | Apr 22, 2025 | |
| ABBV AbbVie | Initiates: Overweight | $210 | $184.60 | +13.76% | 15 | Apr 22, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $165 | $115.71 | +42.60% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $20.02 | -0.10% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $118.17 | +52.32% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $300 → $315 | $265.86 | +18.48% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $69.85 | +43.16% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $0.15 | +1,882.82% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.87 | +246.02% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.18 | +662.71% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $31.70 | +199.73% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $20.28 | -1.38% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $57.55 | +26.85% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $0.33 | +204.88% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.17 | +925.64% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $1.11 | +35.14% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.40 | +462.92% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $252.70 | +50.38% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $58.98 | +39.03% | 5 | Jan 16, 2019 |
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: $535
Current: $424.99
Upside: +25.89%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $46.45
Upside: +18.41%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $527.78
Upside: +31.68%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $22.28
Upside: +7.72%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.16
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $75.97
Upside: +11.89%
Eli Lilly and Company
Apr 22, 2025
Initiates: Overweight
Price Target: $975
Current: $734.57
Upside: +32.73%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $96.91
Upside: +28.99%
AbbVie
Apr 22, 2025
Initiates: Overweight
Price Target: $210
Current: $184.60
Upside: +13.76%
Neurocrine Biosciences
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $115.71
Upside: +42.60%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $20.02
Upside: -0.10%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $118.17
Upside: +52.32%
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $265.86
Upside: +18.48%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $69.85
Upside: +43.16%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $0.15
Upside: +1,882.82%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.87
Upside: +246.02%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.18
Upside: +662.71%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $31.70
Upside: +199.73%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $20.28
Upside: -1.38%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $57.55
Upside: +26.85%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.33
Upside: +204.88%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.17
Upside: +925.64%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $1.11
Upside: +35.14%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.40
Upside: +462.92%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $252.70
Upside: +50.38%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $58.98
Upside: +39.03%